Benutzerspezifische Werkzeuge

Akute myeloische Leukämie

AML: TUD Relax1-070

Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax.Mehr…

AML: Medigene CD-TCR-001

A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR modified T cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms.Mehr…

AML: H3 Biomedicine

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia.Mehr…

AML: UC02-123-01

Multicenter, open-label, adaptive design phase I trial with genetically modified T-cells carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in combination with CD123 target module (TM123) for the treatment of patients with hematologic and lymphatic malignancies ...Mehr…

AML: Army 1

First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid LeukemiaMehr…

AML: Novartis CPDR001X2105

Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic Syndrome.Mehr…

AML: GEM333-01

A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM333, a CD33 Targeted Bispecific Anti- body Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia.Mehr…